RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX)
announced today the pricing of an underwritten public offering of 15,533,981 shares of its common stock, offered at a price to the
public of $5.15 per share. The gross proceeds from this offering to BioCryst are expected to be $80 million, before deducting
underwriting discounts and commissions and estimated offering expenses payable by BioCryst. BioCryst has granted the
underwriters a 30-day option to purchase up to an additional 2,330,097 shares of its common stock. The offering is expected
to close on or about September 15, 2017, subject to customary closing conditions. BioCryst expects to use the net proceeds of
this offering for general corporate purposes, which may include funding the global launch preparation of BCX7353; expanding our
global awareness and commercial and manufacturing efforts; expanding our infrastructure, including commercial and manufacturing, to
benefit BCX7353 and the rest of our programs; supporting the initiation of the Phase 3 clinical trial for BCX7353, the long term
safety study, and all remaining preclinical and clinical studies to support a new drug application filing for BCX7353; funding an
exploratory Phase 2 trial for acute treatment with BCX7353; and advancing our early-stage programs into clinical trials.
J.P. Morgan Securities LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering.
H.C. Wainwright & Co., LLC is acting as co-manager for the offering.
A shelf registration statement on Form S-3 relating to the shares of common stock described above has been
previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). This press release does not
constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
This offering is being made by means of a prospectus supplement and related prospectus. A preliminary
prospectus supplement relating to the offering has been filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement, when available, and accompanying
prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717 or by telephone: 1-866-803-9204 or from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717 or by email: Barclaysprospectus@broadridge.com or by telephone: 1-888-603-5847.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved
in rare diseases. BioCryst has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma
kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential
treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is
BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing
commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other
territories.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results and
achievements, use of proceeds and the completion of this offering. These statements involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance, achievements, or outcomes to be materially different from any
future results, performances, achievements, or outcomes expressed or implied by the forward-looking statements, including risks and
uncertainties associated with market conditions and the satisfaction of customary closing conditions related to this offering and
other risks and uncertainties inherent in BioCryst's business. Please refer to the documents that BioCryst files periodically with
the SEC, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on
Form 8‑K, which identify important factors that could cause the actual results to differ materially from those contained in
BioCryst’s projections and forward-looking statements.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910